NVG-291

DRUG3 trials

Sponsors

NervGen Pharma

Conditions

Chronic Spinal Cord InjurySpinal Cord InjuriesSpinal Cord InjurySubacute Spinal Cord Injury

Phase 1

A Phase I Safety Study of NVG-291 in Healthy Adults

CompletedNCT05308953

NervGen PharmaSpinal Cord Injury

Start: 2021-05-06End: 2023-07-03Updated: 2024-01-10

NVG-291 in Spinal Cord Injury Subjects

CompletedNCT05965700

NervGen PharmaChronic Spinal Cord Injury, Spinal Cord Injuries, Subacute Spinal Cord Injury

Start: 2023-08-08End: 2026-01-21Updated: 2026-06-15

Phase 3

A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury

Not yet recruitingNCT07799532

NervGen PharmaChronic Spinal Cord Injury

Start: 2026-09-23End: 2027-12-14Target: 150Updated: 2026-09-02